*Sponsored by Axe Communications

ONCY is a Blockbuster Biotech Stock Headed into Phase 3 Trials. 

It is Sitting on Massive Cash, has FDA Fast-Track Designation, and Wall Street Analysts Peg The Stock Over 400% Higher From Today’s Price 


As you saw, yesterday’s lithium stock idea produced a double-digit return for those who saw it early.  I really encourage you to keep a close eye on it today as well, and look for follow through.

It just proves that we are on the right track when it comes to winning ideas lately.

Today, I think I have landed on something even BIGGER.

If you have been following the markets this week (or joined my complimentary, live Bullseye session on Monday where I talked about why I bought it before the news), you probably came across a stock that many traders hadn’t heard of until this week – VKTX.

This stock jumped over 100% this week, adding billions in market cap after a successful FDA trial.

I point this out because it goes right along with my observation lately that small biotechs are hot again. 🔥

VKTX lit a fire under traders to find more stocks that might have similar success in the future.

There is one stock that I want you to look at right away that I think fits the bill.

The stock is Oncolytics Biotech (ONCY).

There are several reasons it is so important to look at ONCY right away.

First, consider the price chart.

The stock might be an absolute steal right now, you’ll have to decide that after you read my thoughts on it.

ONCY has dropped more than 50% in the last few months, as traders have abandoned smaller stocks, especially unprofitable biotechs.

With the stock sitting at just over $1 today, I think it presents a tremendous proposition.

Much like buying a stock option, the lowest it can go is $0, right?

But, if they are successful (and I’ll get into why they could be), think of the upside?  It could be mindblowing from this level today. 🤯

If you are wondering why ONCY isn’t making money right now, the answer is simple – they are gearing up to go into a Phase 3 FDA trial (similar to the one VKTX just successfully navigated).

Needless to say, you don’t make money until you have an approved drug… but after that, the sky’s the limit!

That is why you see such huge valuations after a company has cleared Phase 3 approvals.

And get this, the FDA sees such potential for ONCY, they granted them Fast-Track designation to help speed the approval process. 

On top of that, the Pancreatic Cancer Action Network (PanCAN) awarded ONCY with a $5 million grant to further its research.

This will help the company jumpstart its intended “Phase 3” trial in mid-2024, which would officially transition it to a “late-stage” biopharmaceutical company.

As of its Q3 2023 filing, the company had virtually $40 million in cash reserves, which it said in January should be a sufficient “cash runway” to power it for more than 12 months, including the initiation of its Phase 3 trial.

That’s right.  

ONCY as of the last filing, is already sitting on a pile of cold, hard cash of nearly $40 million.

That shows a lot of planning and foresight from the company to build that reserve.

While most retail investors have not been paying attention, analysts on Wall Street have taken notice.

Analysts see the huge potential with ONCY.

In fact, even the most “conservative” analyst estimate puts the stock 400% higher from today’s price, as you can see from the WSJ estimates:

For some background, Oncolytics Biotech Inc. (ONCY) is a clinical-stage biotechnology company at the leading edge of “immunotherapy” cancer research.

In case you don’t know, immunotherapy treatments trigger the body’s own immune system to fight cancer.

At the core of ONCY’s approach is pelareorep, a reovirus that has shown an incredible power to awaken the immune system in order to destroy tumors.

Pelareorep is delivered to the patient intravenously (unlike other immunotherapies which require direct injection into the tumor).

The reovirus then selectively replicates in the cancer cells, inducing “a cascade of inflammatory responses that enable the immune system to destroy the tumor while sparing normal tissue.”

According to the company, “Because pelareorep replicates only in tumor cells, it is well-tolerated by patients.”

I learned from Wikipedia that pelareorep has three main “mechanisms of action”:

The therapy has demonstrated tremendous potential, earning it Fast Track designation from the FDA for the treatment of metastatic breast cancer and a type of advanced pancreatic cancer.

Fast Track is “a designation . . . of an investigational drug for expedited review to facilitate development of drugs that treat a serious or life-threatening condition and fill an unmet medical need.”

And that designation appears to be paying off…

ONCY has several “Phase 2” trials — trials that test the treatment in human patients — ongoing, and has already demonstrated positive results in breast and pancreatic cancers. 

To date, the therapy has been studied in more than 1,100 patients.

According to the company, “When pelareorep was added to standard metastatic breast cancer treatment, overall survival rates nearly doubled in a randomized study of patients with HR+/HER2- breast cancer.” (emphasis added)

In a pancreatic cancer trial, “Interim clinical data showed a 69% objective response rate, which is nearly triple historical control trial averages.”

ONCY has already teamed up with pharma heavyweights such as Roche Holding AG, Pfizer Inc., Merck Serono, Incyte Corporation, and Adlai Nortye to evaluate pelareorep in combination with other therapeutic agents, and there’s no telling where those relationships could lead…

Bottom LineONCY could be a blockbuster opportunity from this level. With analysts raving about it, the company’s sizable cash position, FDA Fast -Track designation, and a $5M award, I think the future is bright for this little company.

Of course, only you can decide what investments fit your personal risk profile. Whatever you do, always trade with a solid game plan that you can comfortably live with. Read all the disclaimers and do as much research on this amazing company as you can today.

I think you will love ONCY as much as I do!

To Your Success,


Jeff Bishop

👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!).  Don’t miss out!


*Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.


*PAID ADVERTISEMENT. RagingBull has currently been paid twenty thousand dollars by ach bank transfer by Axw Communications for advertising Oncolytics Biotech Inc for a one-day advertising program. As a result of this advertisement and other marketing efforts, RagingBull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull do not hold a position in Oncolytics Biotech Inc. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Oncolytics Biotech Inc, increased trading volume, and possibly an increased share price of the Oncolytics Biotech Inc securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in Oncolytics Biotech Inc., though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication.

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.
SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.